
|Videos|October 19, 2017
Dr. Brinda Emu Provides Insight into HIV Monoclonal Antibody Ibalizumab
Author(s)Contagion® Editorial Staff
Brinda Emu, MD, offers insight into the HIV monoclonal antibody ibalizumab.
Advertisement
Brinda Emu, MD, of the Infectious Diseases department at Yale University, offers insight into monoclonal antibody ibalizumab. Dr. Emu explains that the antiretroviral binds CD4—the primary receptor for HIV—and inhibits the viral entry process. Ibalizumab is active against all major HIV clades.
Newsletter
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Contagion Live
1
Once-Weekly Oral Islatravir Plus Lenacapavir Maintains HIV Suppression Through 48 Weeks
2
WHO Certifies Countries as Malaria Free in Face of Persistent Antimalarial Drug Resistance
3
CDC Awards Grant to Study Neonatal Hepatitis B Vaccination Outcomes in Guinea-Bissau
4
Contagion Fall/Winter 2025-2026 Digital Edition
5





























































































































































































































































































